# MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

> **NCT02407405** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 36 (actual)

## Conditions studied

- Neurofibromatosis 1 (NF1)
- Plexiform Neurofibromas (PN)

## Interventions

- **DRUG:** Selumetinib

## Key facts

- **NCT ID:** NCT02407405
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-01-07
- **Primary completion:** 2028-01-01
- **Final completion:** 2030-01-01
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02407405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02407405, "MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02407405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*